A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

Study identifier:D8820C00002

ClinicalTrials.gov identifier:NCT06469151

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5148, Placebo

Sex

All

Estimated Enrollment

84

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 24 Jun 2024
Estimated Primary Completion Date: 18 Feb 2025
Estimated Study Completion Date: 21 Nov 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria